Testing effectiveness (Phase 2)Study completedNCT01079741What this trial is testingSafety Study of Adjuvant Vaccine to Treat Melanoma PatientsWho this might be right forMelanoma Nina Bhardwaj 34
Early research (Phase 1)Study completedNCT04552886What this trial is testingDendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult GlioblastomaWho this might be right forGlioblastoma The Cooper Health System 17
Testing effectiveness (Phase 2)Active Not RecruitingNCT05798663What this trial is testingAtezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLCWho this might be right forNSCLC Alliance Foundation Trials, LLC. 178
Not applicableStudy completedNCT03843593What this trial is testingSee Why Patients Agree To or Decline To Have Treatment After SurgeryWho this might be right forCutaneous Melanoma Memorial Sloan Kettering Cancer Center 38
Early research (Phase 1)Study completedNCT03552718What this trial is testingQUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.Who this might be right forColorectal CancerBreast CancerHead and Neck Squamous Cell Carcinoma+4 more NantBioScience, Inc. 5
Large-scale testing (Phase 3)Active Not RecruitingNCT01436968What this trial is testingPhase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate CancerWho this might be right forProstate Cancer Candel Therapeutics, Inc. 711
Early research (Phase 1)Ended earlyNCT02924038What this trial is testingVarlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)Who this might be right forGliomaMalignant GliomaAstrocytoma, Grade II+3 more Nicholas Butowski 14
Large-scale testing (Phase 3)Looking for participantsNCT06931717What this trial is testingA Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior ChemotherapyWho this might be right forNon-Small Cell Lung Cancer ETOP IBCSG Partners Foundation 390
Testing effectiveness (Phase 2)UnknownNCT05382741What this trial is testingAdjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA TrialWho this might be right forColorectal Cancer Stage IVNo Evidence of Disease State Ospedale Policlinico San Martino 182
Early research (Phase 1)Study completedNCT04853017What this trial is testingELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid TumorsWho this might be right forMinimal Residual DiseaseKRAS G12DKRAS G12R+9 more Elicio Therapeutics 25
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07628062What this trial is testingPhase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard ChemoradiationWho this might be right forHPV-Positive Oropharyngeal Squamous Cell CarcinomaOropharyngeal Squamous Cell CarcinomaHead and Neck Cancer ImmunityBio, Inc. 70
Testing effectiveness (Phase 2)Looking for participantsNCT03740893What this trial is testingPHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast CancerWho this might be right forBreast NeoplasmTriple Negative Breast Cancer (TNBC)HRD Institute of Cancer Research, United Kingdom 119
Testing effectiveness (Phase 2)UnknownNCT05341193What this trial is testingPD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal CarcinomaWho this might be right forNasopharyngeal Carcinoma Sun Yat-sen University 32
Testing effectiveness (Phase 2)UnknownNCT02466906What this trial is testingRhGM-CSF as Adjuvant Immunotherapy in Treating Stage III Colon CancerWho this might be right forColon Cancer The Affiliated Hospital of the Chinese Academy of Military Medical Sciences 60
Testing effectiveness (Phase 2)Looking for participantsNCT07748325What this trial is testingAdjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLCWho this might be right forNon-Small Cell Lung CancerAdjuvant TherapyImmune Checkpoint Inhibitors Sichuan University 100
Post-approval studies (Phase 4)Not Yet RecruitingNCT07149181What this trial is testingComparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regimens in Patients With Resectable Gastric Cancer/Adenocarcinoma of the Esophagogastric Junction After Radical SurgeryWho this might be right forGastric / Gastroesophageal Junction Adenocarcinoma Liaoning Cancer Hospital & Institute 1,000
Not applicableStudy completedNCT06253364What this trial is testingVETC is an Effective Marker for Postoperative Adjuvant ImmunotherapyWho this might be right forHCCRecurrence Chen Xiaoping 462
Early research (Phase 1)Active Not RecruitingNCT02826434What this trial is testingAdjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast CancerWho this might be right forBreast Cancer Massachusetts General Hospital 22
Large-scale testing (Phase 3)Active Not RecruitingNCT04949113What this trial is testingNeoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III MelanomaWho this might be right forMalignant Melanoma Stage III The Netherlands Cancer Institute 423
Testing effectiveness (Phase 2)Looking for participantsNCT05440864What this trial is testingDurvalumab and Tremelimumab in Resectable HCCWho this might be right forHepatocellular Carcinoma University Health Network, Toronto 28